A DBS “extension” is an implanted insulated conductor that links the cranial lead to the IPG, usually by tunneling under the skin from the head toward the chest, where many IPGs are placed.²–⁴ Extensions are not passive plumbing, they experience daily bending, traction, and shear from head turn, shoulder elevation, seatbelts, clothing friction, and scar remodeling, all of which can concentrate mechanical stress at predictable points.¹,⁴–⁸

Routing matters because repeated micro-motion is one of the plausible pathways to lead or extension fracture, connector loosening, or tethering pain, and because certain connector locations have been associated with higher fracture incidence.⁴–⁸

Typical pathway: cranial lead exits at the skull, then the extension is tunneled subcutaneously, commonly passing behind or near the ear and descending along the lateral neck toward the clavicle, then across to the IPG pocket (often infraclavicular).²,³

Why the neck is a “stress corridor”: cervical rotation and flexion create repetitive bending, and if a connector junction sits in soft neck tissues, the junction can behave like a stiff hinge that focuses stress.⁴,⁵

Manufacturer safety language: FDA-approved labeling for DBS systems includes a warning not to place the lead-extension connector in soft tissues of the neck, due to an increased incidence of lead fracture.⁴,⁵

Practical consequence: two patients can have identical brain lead placement and stimulation settings, yet very different long-term hardware comfort and durability because their extension and connector geometry differs.¹,⁶–⁸

Surgeons choose extension paths that balance distance, cosmetic considerations, patient anatomy, and an attempt to minimize mechanical strain.²,³,⁶ Different pathways move the highest-stress points to different parts of the body, and they change where scar bands can “grab” the extension over time, sometimes producing tethering or the sensation of a tight cord.⁶,⁷

Here are some common extensiuon pathways:

• Postauricular or mastoid region toward chest: This pathway is often used for concealment and direct tunneling, but connector positioning in head and neck regions has been associated with fracture patterns in long-term series.⁴,⁸
  

• Parietal or cranial connector strategies: Some systems and surgical styles place junctions more cranially; a large operative series found extension length and connector location were associated with different risks, fracture versus tethering, suggesting there is no single “perfect” route.⁶
  

• Lateral neck descent versus more posterior descent: This is a more superficial or more anterior route may be felt more easily, while deeper tunneling can introduce other risks, and manufacturers explicitly caution that tunneling too superficially or too deeply can cause unintended injury.⁵
  

• Comfort linkage: Discomfort is not only “pressure,” it can be traction from neck motion, focal tenderness over a junction, or cable tethering, and these can overlap with pocket discomfort, making localization clinically challenging.¹,⁶,⁷

Talk with your medical team about what is the best pathway for your condition and be sure to ask why. Asking your medical team "why" gives you a better understanding, and doesn't make you a difficult patient. You are your best advocate!

A strain relief loop is intentional slack, or "extra" leads or extensions so that normal movement pulls on a curve of cable rather than on a fixed junction or a lead anchored at the skull.⁴,⁶,⁷ In mechanical terms, slack reduces peak strain by distributing displacement across a longer length, like giving a river more room to bend so it does not cut a sharp bank.⁶,⁷ Without slack, motion can transmit force directly to the connector set-screw junction or to the intracranial lead anchoring point, increasing risk of mechanical fatigue or disconnection.⁴,⁶

Here are locations where extra slack is commonly placed and why:

• Near the skull exit or behind the ear: At this location the extra slack can buffer head rotation and reduce direct traction on the cranial fixation site.⁴,⁶
  

• Along the neck and clavicle transition: Since this region experiences frequent motion and can be a point of repeated bending; controlled slack aims to reduce “hinge” behavior.⁶,⁷
  

• Near the IPG pocket entrance: This location of extra slack can reduce torque transmission to the IPG, potentially lowering the chance of device rotation in the pocket contributing to cable twisting.¹,¹⁵,²⁷
  

• Evidence boundary: In this location, slack is a surgical strategy supported by biomechanical logic and complication pattern recognition, but there is not a single standardized, universally proven “optimal” slack geometry across all systems.⁶,⁷

When you first have DBS implanted, it is normal to feel like you may pull out your leads, extensions or any of the cabling you may feel, but your medical team places extra for the purpose of flexibility. In many cases individual with unilateral (1) lead and bilateral (2) leads have treatment from their chiropractic doctor or massage therapist without problems.

Ask your medical team what they recommend for you to do, and not to do, as well as the time frame where you are free and clear to resume normal activities.

A connector block is the junction where the cranial lead meets the extension, often secured by set screws and covered by a protective boot or sleeve, forming both an electrical interface and a mechanical transition zone.⁴ The junction is critical because it is relatively stiff compared with the cable, and stiffness mismatches are classic sites for stress concentration and fatigue in implanted conductors.⁴,⁶

Here are options your medical team may use for placement: Cranial or subgaleal region: The junction can be placed under scalp tissues; this can be cosmetically hidden but may be exposed to pressure from helmets, headrests, or thin tissue coverage in some individuals.⁶,⁸

Postauricular or mastoid region: This is commonly discussed in fracture series, with fractures sometimes occurring near connection sites placed in these regions.⁸

Cervical soft tissue region: FDA labeling warns against connector placement in soft tissues of the neck due to increased fracture incidence.⁴,⁵

Near the clavicle or upper chest: Junction placement lower than the neck can reduce cervical bending stress at the junction, although it changes tunneling length and potentially tethering patterns.⁶,⁷

Electrical reality is where “high impedance” readings can reflect a true open circuit, a connector issue, or a lead problem, which is why troubleshooting frameworks emphasize evaluating the whole chain from IPG to lead rather than assuming the brain lead is at fault.⁹

As always, if you have further questions, have discussions with your medical team about what is best for you and your DBS plan of care.

The “pocket”, also referred to as a "chest pocket", is the surgically created space that holds the IPG, typically under the skin in the upper chest, although other locations exist.¹–³ Pocket design is not only about fitting the device, it is about tissue thickness, minimizing motion of the device, ensuring the device can communicate with external controllers, and, for rechargeable systems, ensuring RF charging can couple effectively through tissue.¹–³

Here are some common pocket-related issues and why they happen:

• Pocket discomfort: This can be from early from inflammation or later from mechanical pressure, device edge irritation, or scar tightening, and it can be hard to distinguish from extension discomfort because they can coexist.¹,²¹
  

• Hematoma or seroma: Fluid collections are recognized surgical-pocket complications in DBS series and can increase discomfort and infection risk.²¹–²³
  

• Skin thinning and erosion: When tissue coverage is thin or under chronic pressure, the device can threaten skin integrity; erosion can precede or coexist with infection, and it is a major reason some systems require revision.¹,²¹,²³
  

• Device rotation, “flipping,” or Twiddler-like behaviors: Potential IPG rotation inside the pocket can twist the extension and may contribute to hardware failure; case reports describe generator manipulation or rotation leading to therapy disruption and revision.¹,²⁷
  

• Communication and charging failures: If the IPG is too deep or malpositioned, external communication and charging can be impaired, and clinician manuals specify pocket depth limits for reliable device communication in at least some systems.²,¹⁵

It should be noted that these potential problems may not be expected to happen for you, but understanding the potential complications helps you have a better understanding, and conversation with your medical team if you think you are experience problems.

“Pectoral” placement typically means infraclavicular upper chest placement, while “abdominal” placement places the IPG in the abdominal wall region, which usually requires longer tunneling and extension length.¹–³ The choice is often a trade between tissue thickness, comfort, cosmetic goals, surgical history, and practical tasks like recharging and device interrogation, all while maintaining a safe mechanical route.¹–³,⁶

Some DBS patients may experience: Tissue thickness and skin risk: This is when there is thinner skin coverage over the chest can increase skin pressure concerns, while abdominal tissue can provide more padding for some bodies, although this varies.¹,²¹,²³

Mechanical length: Abdominal placement of your IPG will generally increases the extension length, and longer routing can change tethering and fracture dynamics.⁶,⁷

Recharge practicality: Rechargeable IPG's may depend on external-to-implant coupling; deeper placement or challenging geometry can make charging harder in some cases.¹,¹⁵

Revisions and prior surgeries: If you have to have your IPG replaced, prior chest devices, scars, or infections may influence site choice, because reusing scarred tissue planes can affect wound risk and hardware stability.²¹–²³

As always, with any concerns, reach out to your DBS medical team.

An IPG is the implanted “power and control” unit for DBS (AKA - The Battery!), delivering programmed electrical pulses through the implanted leads and extensions.¹–³ A cardiac pacemaker also delivers pulses, but it targets heart conduction tissue, typically senses intrinsic cardiac signals continuously, and follows cardiac-specific timing logic, whereas DBS targets neural circuits and may or may not include brain sensing depending on the model.¹,²⁵

Here are the key differences :

• Target tissue and lead environment: DBS electrodes sit in brain tissue, and the electrode-tissue interface changes over time in ways that can alter impedance; cardiac leads exist in a different mechanical and ionic environment.¹⁰–¹²
  

• Output goals: DBS is tuned to modulate neural activity and symptoms, while pacemakers primarily maintain adequate heart rhythm and rate.¹–³,²⁵
  

• Device interactions: Patients can sometimes have both DBS and cardiac devices; reviews suggest implantation can be safe with precautions, but management is multidisciplinary and device-specific.²⁵
  

• Electromagnetic environments: Both the IPG and the Pacemaker have EMI considerations, but DBS has specific warnings around diathermy and MRI conditions that must be followed by labeling.²–⁵,²⁴

Even though you may have a Pacemaker first, or DBS first, you can still have both installed at the same time. Often some patients have a dual DBS system where the IPG is located in two different locations. Some have received 2 DBS system for Parkinsons, and some patients have had one for Depression and another for Pain. It all depends on your own specific biology and your treatment plan of care that your medical team deems appropriate for your needs.

The IPG (battery/generator) controls stimulus delivery, which usually means amplitude, pulse width, frequency, contact selection, and sometimes field shaping via current distribution across contacts, depending on system capabilities.²,³,¹³,¹⁴ It also performs safety monitoring, impedance checks, and power management, and it may store therapy programs and event logs.²,³,⁹

What the IPG controls:

• Stimulation waveform parameters: This includes amplitude, pulse width, frequency, and polarity configuration, which determine delivered charge per pulse and energy use.³,¹³,¹⁶,¹⁷
  

• Contact configuration: This is how the contact emits the therapy such as in monopolar, bipolar, or more complex multipolar patterns. Different configuration can change electric field shape and can affect both efficacy and battery drain.¹⁶,¹⁷
  

• Power mode: This is the type of energy that the IPG emits. This can include constant-voltage or constant-current output, which changes how stimulation responds to impedance variability.¹³,¹⁴
  

• Device communications: The IPG also acts as the connection for clinician programmers and patient controllers, which can fail if the device is placed too deep or if other factors interfere.²
  

What the IPG doesn't control:

• Disease progression: DBS is a symptomatic therapy and does not remove the underlying pathology of most conditions it treats, even when symptom response is strong.²,³
  

• All symptom variability: Medication changes, sleep, stress, illness, and progression can shift symptoms even if stimulation hardware and settings remain stable.³
  

• Safety in restricted procedures: The device cannot “auto-protect” against contraindicated procedures such as diathermy, which is why explicit labeling warnings exist.²–⁵,²⁴

Glossary:

• Amplitude: How “strong” each stimulation pulse is. In DBS it is usually set as voltage (V) or current (mA), and it is often the main dial that changes symptom control and side effects.
  

• Pulse width: How long each individual pulse lasts, measured in microseconds (µs). Longer pulse widths deliver more charge per pulse and can recruit more tissue, sometimes helping symptoms but also increasing side-effect risk.
  

• Frequency: How often pulses are delivered, measured in hertz (Hz), meaning pulses per second. Higher frequencies generally feel “steadier” and can suppress some symptoms better in common DBS indications, but may use more energy and can change side-effect patterns.
  

• Polarity configuration: Which contact(s) act as the negative electrode (cathode, −) and which act as the positive electrode (anode, +), plus how the case (the IPG “can”) is used. This configuration strongly affects where stimulation concentrates in the brain.
  

• Monopolar: A configuration where one or more contacts are active (commonly cathode) and the IPG case serves as the return path (commonly anode). It usually creates a broader stimulation field, which can be efficient for coverage but may cause side effects if the field spreads into nearby structures.
  

• Bipolar: A configuration where contacts on the lead provide both the cathode and anode (no can return, in classic bipolar). This often creates a more focused field between contacts, which can help narrow stimulation and sometimes reduce side effects, with tradeoffs in energy use and programming complexity.
  

• Electric field shape: The 3D “footprint” of stimulation in tissue, basically where the voltage gradient and current density spread around the lead. It is shaped by contact selection, monopolar vs bipolar (or more complex multi-contact patterns), directional steering, pulse settings, and tissue/electrode impedance, and it is the practical reason programming can feel like “aiming” rather than just “turning up power.”
  

• Constant-voltage output: The device holds voltage constant, and the current changes depending on impedance (which can vary across people and over time). Translation: the same voltage setting can deliver different current on different days or in different tissue conditions.
  

• Constant-current output: The device holds current constant, and the voltage adjusts as impedance changes to maintain that current. Translation: it aims to deliver a more consistent “dose of current,” which can make stimulation delivery more stable across impedance shifts, though the device may need to raise voltage to do it.

The simplest way to frame the difference is through "Ohm’s Law" which states:

With constant-voltage stimulation, the device holds voltage steady and delivered current changes when impedance changes; with constant-current stimulation, the device holds current steady and varies voltage as needed to overcome impedance changes.¹³,¹⁴

Because impedance can drift over time due to tissue encapsulation and electrode interface changes, the same programmed voltage may not yield the same current months or years later, while constant-current systems attempt to stabilize current delivery.¹⁰–¹²,¹³

Here are some clinical and technical implications:

• Stability versus simplicity: constant-current aims for consistent current delivery across impedance drift, while constant-voltage can be more directly related to older programming conventions; real-world outcomes depend on many factors.¹³,¹⁴
  

• Impedance events: sudden high impedance can indicate an open circuit; constant-current devices may drive voltage higher to maintain current until safety limits are reached, which can change symptom control and troubleshooting interpretation.⁹,¹³
  

• Evidence boundary: studies comparing constant-current and constant-voltage report broadly comparable clinical outcomes in many contexts, with differences often relating to programming behavior and impedance sensitivity rather than dramatic efficacy gaps.¹³,¹⁴
  

The mode changes how you interpret changes in symptom control when impedance drifts, and why “the same settings” may not mean the same delivered dose over time.¹⁰–¹⁴

Impedance is the effective opposition to current flow in the DBS circuit, including the electrode-tissue interface, the encapsulation layer that forms around electrodes, and the conductive path through extensions and connectors.¹⁰ It's not a single material property, but a system measurement that can change over time, after contact activation, and with tissue remodeling.¹⁰–¹² Measuring impedance helps teams detect gross hardware problems, such as open circuits and short circuits, and also helps contextualize why stimulation effects may change even when settings look “unchanged.”⁹–¹²

What are potential impedance issues:

• Gradual decrease over time: Studies show that impedance can decrease over months to years, with influence by stimulation history and contact usage, which has implications for long-term programming.¹¹,¹²
  

• High impedance: If your medical team finds a high impedance can suggest an open circuit, connector issue, or lead break, and should trigger a stepwise evaluation of the system rather than assumptions.⁹
  

• Low impedance: If your medical team finds low impedance, it can suggest a short circuit or insulation breach, also requiring systematic evaluation.⁹
  

In constant-voltage mode, changes in impedance can directly change delivered current; in constant-current mode, changes in impedance may change required voltage, affecting battery use and safety margins.¹³

As always, this is why having clinic visits with your medical team is important. Keeping tabs on the impedance of your DBS system will keep if working smoothly. As always, if you feel anything unusual or your DBS therapy is not controlling your symptoms, reach out to your medical team immediately.

The electrode-tissue interface is the physical and electrochemical boundary where the metal contact meets biological tissue and encapsulation layers; it influences both measured impedance and how stimulation spreads.⁸,⁹

As referred to earlier, impedance testing is a key tool to identify suspected open circuits (very high impedance) or short circuits (very low impedance) within DBS hardware, including lead, extension, and connector segments.¹⁰,⁸,¹¹

Impedance values also help interpret the spread of stimulation and the stability of therapy delivery over time, not only “hardware broken or not.”⁸,⁹

Impedance is often used clinically to flag broken leads at high values and short circuits at very low values, while also emphasizing that values can shift for reasons beyond breakage.⁸

Common hardware failure concepts can be as follows:

• Conductor fracture: a break in the wire conductor that can produce intermittent or complete open circuits, often associated with repetitive motion and stress points.¹²,¹³
  

• Insulation breach or short: can create unintended current paths, abnormal impedances, or ineffective stimulation.¹⁰,¹¹
  

• Connector or set-screw issues: imperfect seating, loosening, or micro-motion at junction points can affect continuity and can be evaluated via impedance testing and imaging pathways.²,¹¹
  

A neurosurgical risk-factor analysis links fracture and tethering risk to extension length choices and connector location strategy, and cautions that some strategies can trade lower fracture risk for higher tethering risk.¹²

Mechanical and comfort:

• Rotation within the pocket can twist extensions and jeopardize therapy continuity, described in DBS and other implantable device contexts.²⁷
  

• Discomfort can reflect local pressure, pocket depth, device contour, or scar behavior; it is not automatically a “stimulation” problem.²¹

Skin and wound integrity

• Skin thinning, wound dehiscence, and erosion are recognized DBS wound complication patterns, sometimes occurring at the IPG pocket and sometimes at connector sites.²¹
  

• Manufacturer warnings also emphasize avoiding manipulation of implanted components because it can contribute to component damage and skin erosion.¹

Infection risk drivers

• Infection risk is higher in the early postoperative period and after revision procedures in many surgical-device contexts; DBS series describe infections both after initial implantation and after generator replacement.¹⁸,¹⁹,²²

DBS device-related infections can occur early after implantation or later, but the early post-operative period is commonly emphasized because surgical wounds are fresh and bacterial inoculation risk is highest during and soon after surgery.²¹–²³ Studies and series describe infection as a clinically meaningful complication that can disrupt therapy and require antibiotics, revision, or device removal, depending on depth and severity.²¹–²³

Warning signs to take seriously and report to a clinician urgently:

• New or worsening redness, warmth, swelling, drainage, or wound opening near the scalp incisions, along the neck tunneling path, or at the chest pocket site.²¹–²³
  

• Fever or systemic illness in combination with wound changes.²¹–²³
  

• New focal tenderness over a connector or the pocket that progresses rather than improves.²¹–²³
  

• “Typical timing” varies by center and by definition of infection, so it is better to use symptom-based vigilance rather than a calendar rule.²¹–²³

When you are scheduled for DBS surgery, your medical team should go over ways to prep your home from potential infection sources, such as pillow covers and bedding, animal concerns, and any other options that could lead to infection. Typically when you have pre-op registration with your medical center where the DBS surgery is going to be done, they give you an anti-bacterial scrub/soap, or they give you explicit instruction on using anti-bacterial soap for before surgery. After surgery, your discharge instructions will go over any potential infection prevention practices and concerns. If you experience any of these call your medical team or the medical facility immediatly. Sometimes, as a preventative measure based on your medical teams plan of care, you may be prescribed an antibiotic to curb off potential infection. This varies from medical team to medical team and from medical facility to medical facility. Ask your medical team what is best for you.

DBS infections are challenging because implanted hardware can support bacterial biofilms, which are structured communities that reduce antibiotic penetration and make eradication difficult without removing colonized material.²²,²³

In practice, management often depends on whether the infection is superficial versus deep, whether there is erosion or exposed hardware, and whether there are signs of pocket involvement, lead involvement, or systemic infection.²¹–²³

Common escalation patterns to be aware of:

• Superficial or early infections: Some studies show attempts at wound care, debridement, and targeted antibiotics, sometimes with partial hardware salvage depending on circumstances.²¹–²³
  

• Pocket infections and exposed hardware: Deeper infections often require hardware removal because retention can lead to recurrence; large institutional experience often favors explantation for deep infection.²²
  

• Staged strategies: Some medical centers use staged explant and reimplant pathways, balancing symptom needs with infection control; exact protocols differ and remain an area of active practice variation.²²,²³
  

• Evidence boundary: The “Salvage Versus Explant” is not settled universally; outcomes vary by organism, depth, host factors, and surgical technique, and this is a decision that must be individualized by the treating team.²¹–²³

Be sure that your medical team is aware of any allergies you may have to antibiotics, including any gastro issues you have had in the past.

Erosion describes breakdown or thinning of overlying skin and soft tissue until hardware is threatened or exposed.¹,²¹ Erosion can occur without overt infection at first, driven by mechanical pressure, fragile tissue, and wound healing limitations, but once hardware is exposed, infection risk rises sharply because the skin barrier is compromised.¹,²¹–²³

Why erosion happens in DBS:

• Bulk under skin: Since the IPG is a sizable foreign body in a confined pocket, and chronic edge pressure, both can compromise microcirculation.¹,²¹
  

• Thin tissue planes: With limited subcutaneous fat, or prior surgeries, padding can be reduced and the risk increase becomes more prominant.¹,²¹
  

• Micro-motion: Repetitive movement between device and tissue can act like slow abrasion, especially over prominent edges.¹
  

Clinicians often treat erosion as a high-priority problem even if infection signs are mild, because exposure changes the risk profile and often pushes decisions toward revision or removal.²¹–²³

If you have concerns, please reach out to your medical team immediately!

Non-rechargeable IPGs use a primary cell that depletes over time, then the IPG is replaced surgically when it reaches replacement thresholds.¹,²,¹⁹,²⁰ Often these non-rechargable batteries can be effective up to 5 years, depending on your programming.

Rechargeable IPGs require regular external charging, typically through RF coupling, and in exchange they can reduce the frequency of replacement surgeries for some stimulation settings and use patterns.¹–³,¹⁵

Here are some considerations specific to Rechargable vs Non:

• Routine burden: Rechargeable systems require consistent charging habits, comfort with chargers, and adequate coupling through tissue, while non-rechargeable systems shift burden toward periodic surgeries.¹,¹⁵
  

• Charging complications: Some case studies show rare, but real, charging difficulties that sometimes require surgical revision, including anchoring strategies, highlighting that recharge is a technology plus an anatomy problem, not just a user problem.¹⁵
  

• Depth and placement sensitivity: clinician manuals specify placement considerations because device depth can impede communication; this can intersect directly with charging reliability.²
  

• Evidence boundary: The “best” choice depends a few considerations: Your specific stimulation energy needs, Your ability to maintain recharge routines, and If it's the right choice for your individualized plan of care.¹,¹⁵–¹⁷

Battery longevity is influenced by the energy that is delivered based on your plan of care which depends on stimulation amplitude, pulse width, frequency, impedance, and configuration, plus device-specific overhead such as sensing features or telemetry.¹,¹⁶,¹⁷

In research, it has shown that energy use is often summarized by the total electrical energy delivered (TEED) or related metrics, which correlate with shorter battery life when higher.¹⁷

But what can help the battery to drain faster?

• Higher frequency is associated with shorter longevity in recent longevity analyses.¹⁷
  

• Longer pulse width generally increases charge per pulse, increasing energy use and reducing longevity.¹⁷
  

• Higher amplitude increases delivered charge and energy.¹⁶,¹⁷
  

• The stimulation mode affects longevity; a clinical practice study found bipolar mode associated with longer longevity than monopolar in that cohort, and double monopolar associated with shorter longevity.¹⁶
  

• In constant-current systems, voltage may rise to maintain current if impedance rises, affecting energy use; in constant-voltage systems, current changes with impedance.¹³
  

Exact longevity predictions vary on what the manufacturer documents, and also based on your specific DBS therapy needs.¹,¹⁶,¹⁷

We addressed some of these topics previously, but lets look a bit deeper on how these parameters define the “dose” of electrical stimulation and directly shape both neural activation and power consumption.¹³,¹⁶,¹⁷

Conceptually, you can treat amplitude and pulse width as defining charge per pulse, and frequency as defining how often that charge is delivered; multiply them and you get a first-order sense of energy demand, then add the device’s efficiency and impedance effects.¹³,¹⁶,¹⁷

Parameter-by-parameter, what tends to happen:

• Amplitude: Increasing amplitude increases delivered charge and typically increases energy demand, often shortening longevity.¹⁶,¹⁷
  

• Pulse width: Increasing pulse width increases charge per pulse and can shorten longevity, and it can also alter the therapeutic window in some contexts.¹⁷
  

• Frequency: Increasing frequency increases pulses per second, often one of the strongest correlates of shortened longevity in some datasets.¹⁷
  

• Contact configuration: mmultipolar patterns can improve field shaping but may increase total current paths and energy use, depending on how current is distributed; configuration has shown measurable longevity differences in practice cohorts.¹⁶
  

• Impedance monitoring: Because impedance can change, the same programmed parameters may not equate to the same delivered current or voltage demands over time, which is one reason follow-up measurements matter.¹⁰–¹³

A low battery doesn't have a single unique “feeling,” because battery depletion typically manifests itself as reduced, or interrupted therapy delivery, which often looks like a return of the symptoms that DBS was helping control.²,¹⁸–²⁰

Manufacturers and clinician manuals warn that abrupt reduction of DBS therapy can cause symptoms to return, sometimes with rebound intensity, and in rare cases this can be a medical emergency.²,³

Additionally, clinical literature reports worsening symptoms associated with depleted battery voltage, reinforcing that battery status is clinically meaningful.¹⁸

Symptoms and scenarios to look out for:

• True stimulation reduction: This is when symptoms return that parallels the loss of therapy, especially if device logs or indicators show depletion thresholds.²,¹⁸–²⁰
  

• Hardware discontinuity: Intermittent open circuits or connector problems can mimic depletion by intermittently interrupting therapy, which is why troubleshooting frameworks emphasize impedance and device checks.⁹
  

• Programming drift or impedance drift: Changing impedance over time can change delivered dose, which can mimic depletion if symptom control gradually fades.¹¹–¹³
  

• Non-device causes: Medication changes, sleep deprivation, illness, stress, and disease progression can all mimic “battery low” because they change symptom expression, even when the device is stable.³
  

Because symptom return can be severe for some conditions and some individuals, battery concerns should be evaluated promptly by the treating DBS team, and urgent deterioration warrants emergency evaluation.²,²⁰

"Elective Replacement Indicator" (ERI), is a warning that the device is nearing the end of its service life and replacement planning should begin, while "End of Service" (EOS), indicates the device has reached a point where therapy may no longer be delivered adequately or may stop.²⁰

For DBS specifically, DBS manufacturers define what your DBS system will state and emphasize replacement planning at ERI and replacement at EOS to avoid loss of therapy.²⁰ Some manufacturer safety communications have also highlighted that the time between ERI and EOS can be shorter than expected in certain device populations, which raises the importance of timely follow-up.¹⁹

ERI is a planning window where the goal is to schedule evaluation and replacement planning before therapy interruption occurs.²⁰ EOS is a higher-risk state implying that your device may not reliably deliver therapy, increasing risk of symptom return.²⁰

Not all systems behave identically and how the manufacturers define these differences, along with any safety notices, indicate that the ERI-to-EOS interval can differ from labeling expectations in some device subsets.¹⁹ Since exact timing from ERI to EOS varies by device model, use conditions, and manufacturer design; patients should rely on their device checks and clinician guidance, not generalized timelines.¹⁹,²⁰ Again, this is why regular scheduled visits with your medical team is important. They track all of this information and can give reliable recommendations and any changes in your plan of care.

IPG replacement is usually less invasive than initial brain lead implantation because it typically focuses on reopening the pocket site, disconnecting and reconnecting extensions, and securing the new IPG.¹,²¹

However, replacement isn't questionable, because pocket revisions carry risks of infection, hematoma, discomfort, and wound problems, and infection risk is a major reason replacement timing matters.²¹–²³ Replacement also interacts with the mechanical history of the pocket, scar tissue, and prior device positioning, which can influence comfort and the risk of rotation or erosion.¹,²¹,²³

What can make replacement easier or harder:

• Tissue condition: Thick, healthy coverage can support more straightforward pocket healing, while thin or scarred tissue can increase erosion and wound complication concerns.¹,²¹,²³
  

• Prior infection history: Prior infection substantially changes planning, often involving staged strategies and careful risk reduction.²²,²³
  

• Rechargeable versus non-rechargeable: Rechargeable systems reduce replacement frequency but introduce a long-term “charging interface” to manage; non-rechargeable systems concentrate burden in periodic surgeries.¹,¹⁵
  

Surgical details vary by device type, center practice, and individual anatomy. You should always ask your surgeon what changes, and what stays the same, compared with the original procedure.²¹–²³

DBS systems have specific contraindications and precautions because strong electromagnetic fields can induce unintended currents, cause heating at leads, disrupt programming, or damage electronics.²–⁵,²⁴

FDA labeling and manufacturer manuals prominently contraindicate diathermy, and MRI safety depends on the exact system components and the manufacturer’s MRI-conditional labeling.²–⁵,²⁴ A practical safety principle used by patient programs is: always inform every healthcare provider about DBS hardware, and follow device-specific instructions for imaging and procedures.²–⁵,²⁴

High-yield categories of exposure:

• Diathermy which is repeatedly contraindicated in DBS labeling and manuals, due to risk of severe injury or death from energy transfer through implanted systems.²–⁵
  

• MRI is allowed only when the full system is MRI-conditional under specific conditions, and older manuals may list MRI as contraindicated depending on system and generation; always follow the exact labeling for the implanted components.²,³,²⁴
  

• In surgical electrocautery and external energy devices, special precautions are commonly required; institution guides emphasize coordinating with the DBS team and using device-specific safety steps.²⁴
  

• Security systems and strong fields can interact and that strong fields can affect devices, emphasizing carrying your patient programmer and medical ID.²⁴
  

EMI risk is device- and context-specific; do not generalize rules from one manufacturer or one generation to another.²,³,²⁴ Always talk to your DBS medical team about concerns!

DBS troubleshooting, when done correctly, is a structured evaluation of the entire chain, IPG, extension, connector, and lead, using device interrogation, impedance measurements, and symptom context.⁹

High therapeutic impedance and lead integrity impedance can mean different things, and systematic approaches help separate open circuits from short circuits and localize faults.⁹

These are ways your medical team may check your system:

• Start with interrogation by reviewing the battery status indicators, logs, and whether the device reports ERI or EOS states.²⁰
  

• Impedance pattern recognition where high impedance can suggest open circuit, low impedance can suggest short circuit; interpretation depends on system definitions.⁹–¹³
  

• A recommended approach will evaluate the system stepwise from IPG outward to isolate whether the fault is near the IPG, the extension, the connector, or the intracranial lead.⁹
  

• Your medical team will match your impedance and battery data with symptom timing, because abrupt symptom return can reflect sudden therapy cessation from many causes.²,⁹
  

There's no universally established guidelines for every malfunction scenario, and device-specific behaviors differ, so troubleshooting is both science and experienced clinical craft.⁹ This is why you rely on the expertise of your medical team.

DBS systems are regulated and labeled differently across countries, and the same brand name may map to different generations or MRI-conditional status by region and approval date.²,³,²⁴

Recharge hardware, telemetry behaviors, and even battery indicator terminology can also vary between manufacturers and between regions, so patients and clinicians should verify the exact model and the locally approved labeling rather than relying on general internet descriptions.²,³,¹⁹,²⁰

If symptoms are urgent or severe, seek emergency care.²,²⁰ such as:

• Sudden, severe return of symptoms that causes inability to breathe safely, stand safely, swallow safely, or function safely.²
  

• New confusion, fainting, severe weakness, or other alarming neurologic changes, especially if they coincide with suspected abrupt therapy cessation.²
  

• Fever with spreading redness, drainage, rapidly worsening swelling, or an opening wound near any DBS incision or the IPG pocket.²¹–²³
  

• Any situation where you believe there is an emergency, even if you are not sure whether DBS is involved.

Keep your closes medical centers contact information where you can find it, and put your medical device representative and your medical teams phone numbers in your phone. If you are experiencing concerns, keep calling one or all until you get someone to answer!

Even with strong clinical experience, several areas remain uncertain because they depend on individual anatomy, long-term tissue remodeling, and device-specific engineering.¹,⁶,⁷ For example, connector location is associated with fracture risk patterns in large series, yet optimal placement is not identical for every person because tethering risk and comfort can move in opposite directions.⁶,⁷

Likewise, constant-current versus constant-voltage comparisons often show broadly similar symptom outcomes, but they can differ in how impedance drift influences programming behavior, and long-term head-to-head evidence across all targets and devices is still developing.¹³,¹⁴

Here are some important questions to ask your DBS team:

• “Where are my connector junctions located, and why was that location chosen for me?”⁴–⁸
  

• “How does my system report ERI and EOS, and what is our replacement plan if the interval is shorter than expected?”¹⁹,²⁰
  

• “Do my implanted components make me MRI-conditional, and under what exact conditions?”²–⁵,²⁴
  

• “If I ever have sudden symptom return, what is our stepwise plan to check battery status, impedance, and hardware continuity?”⁹,²⁰

Remember that your are your own best advocate. Ask your medical team any and all questions until you understand the answer to what you are asking! Your voice matters in your plan of care!

1. Sarica C, Iorio-Morin C, Fomenko A, et al. Implantable pulse generators for deep brain stimulation: challenges, complications, and strategies for practicality and longevity. Front Hum Neurosci. 2021;15:708481. doi:10.3389/fnhum.2021.708481. PMCID: PMC8427803. https://pmc.ncbi.nlm.nih.gov/articles/PMC8427803/
   

2. Abbott Medical. Infinity Deep Brain Stimulation System Clinician’s Manual (PMA P140009/S039). FDA labeling PDF. https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140009S039D.pdf
   

3. Boston Scientific. Vercise Deep Brain Stimulation System Physician Manual (eLabeling PDF). https://www.bostonscientific.com/content/dam/elabeling/nm/91098825-10A_Vercise_Physician_Manual_OUS_ML_s.pdf
   

4. US Food and Drug Administration. Medtronic DBS Therapy professional labeling, includes warning: do not place lead-extension connector in soft tissues of the neck due to increased lead fracture incidence (example labeling document). https://www.accessdata.fda.gov/cdrh_docs/pdf5/H050003d.pdf
   

5. Medtronic. Deep brain stimulation, important safety information, includes tunneling cautions and connector placement warning language across patient safety pages. https://www.medtronic.com/en-us/l/patients/treatments-therapies/what-is-dbs/important-safety-information.html
   

6. Mackel CE, Papavassiliou E, Alterman RL. Risk factors for wire fracture or tethering in deep brain stimulation: a 15-year experience. Oper Neurosurg (Hagerstown). 2020;19(6):708-714. PMID: 32710790. https://pubmed.ncbi.nlm.nih.gov/32710790/
   

7. Fenoy AJ, Simpson RK Jr. Wire tethering, or “bowstringing,” as a long-term hardware-related complication of deep brain stimulation. Stereotact Funct Neurosurg. 2009;87(6):353-359. PMID: 19752594. https://pubmed.ncbi.nlm.nih.gov/19752594/
   

8. Fernández FS, Alvarez Vega MA, Antuña Ramos A, et al. Lead fractures in deep brain stimulation during long-term follow-up. Parkinsons Dis. 2010;2010:409356. PMID: 20975776. https://pubmed.ncbi.nlm.nih.gov/20975776/
   

9. Deeb W, Patel A, Okun MS, Gunduz A. Management of elevated therapeutic impedances on deep brain stimulation leads. Tremor Other Hyperkinet Mov (N Y). 2017;7:493. doi:10.5334/tohm.370. PMCID: PMC5628334. https://pmc.ncbi.nlm.nih.gov/articles/PMC5628334/
   

10. Butson CR, Maks CB, McIntyre CC. Sources and effects of electrode impedance during deep brain stimulation. Clin Neurophysiol. 2006;117(2):447-454. doi:10.1016/j.clinph.2005.10.007. PMID: 16376143. PMCID: PMC3692979. https://pmc.ncbi.nlm.nih.gov/articles/PMC3692979/
    

11. Lempka SF, Miocinovic S, Johnson MD, et al. Variation in deep brain stimulation electrode impedance over years following electrode implantation. Neuromodulation. 2015;18(1):21-31. PMID: 24503709. PMCID: PMC4531050. https://pmc.ncbi.nlm.nih.gov/articles/PMC4531050/
    

12. Satzer D, Lanctin D, Eberly L, et al. Deep brain stimulation impedance decreases over time even when stimulation settings are held constant. Front Hum Neurosci. 2020;14:584005. doi:10.3389/fnhum.2020.584005. https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2020.584005/full
    

13. Ramirez de Noriega F, Eitan R, Marmor O, et al. Constant current versus constant voltage subthalamic nucleus deep brain stimulation in Parkinson’s disease. Stereotact Funct Neurosurg. 2015;93(2):114-121. doi:10.1159/000368443. PMID: 25721228. https://pubmed.ncbi.nlm.nih.gov/25721228/
    

14. Constant current versus constant voltage: clinical evidence of differences in deep brain stimulation. Stereotact Funct Neurosurg. 2020. PMID: 33227781. https://pubmed.ncbi.nlm.nih.gov/33227781/
    

15. Li H, Su D, Lai Y, et al. Recharging difficulty with pulse generator after deep brain stimulation: a case series of five patients. Front Neurosci. 2021;15:705483. doi:10.3389/fnins.2021.705483. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.705483/full
    

16. Fisher RS, et al. Deep brain stimulation battery longevity: comparison of monopolar versus bipolar stimulation modes. Mov Disord Clin Pract. 2016;3(4):359-366. doi:10.1002/mdc3.12285. PMID: 27617270. PMCID: PMC5015697. https://pmc.ncbi.nlm.nih.gov/articles/PMC5015697/
    

17. Yazdanian F, Enriquez-Marulanda A, Dehmamy N, et al. Battery longevity in deep brain stimulation for Parkinson’s disease. Stereotact Funct Neurosurg. 2025;103(4):227-235. doi:10.1159/000544714. PMID: 40388898. https://pubmed.ncbi.nlm.nih.gov/40388898/
    

18. Sidiropoulos C, et al. Depleting implanted pulse generator (IPG) battery voltage is associated with worsening clinical symptoms in movement disorder patients receiving deep brain stimulation. Neurol Neurochir Pol. 2021. PMCID: PMC8288559. https://pmc.ncbi.nlm.nih.gov/articles/PMC8288559/
    

19. Abbott Medical. Urgent Medical Device Correction: Infinity DBS System, ERI behavior communication (physician letter). May 30, 2024. https://www.neuromodulation.abbott/content/dam/nm/neuromodulation/downloadables/productadvisories/060724_orioneri/PhysicianLetter_US_30May2024-DBSSigned.pdf
    

20. Medtronic Academy. Battery status definitions for DBS, includes ERI and EOS descriptions. https://www.medtronicacademy.com/en-us/document/battery-status/DBS
    

21. Fenoy AJ, Simpson RK Jr. Management of device-related wound complications in deep brain stimulation surgery. J Neurosurg. 2012;116(6):1324-1332. doi:10.3171/2012.1.JNS111798. PMID: 22404671. https://pubmed.ncbi.nlm.nih.gov/22404671/
    

22. Tabaja H, Yuen CM, Baddour LM, et al. Deep brain stimulator device infection: the Mayo Clinic Rochester experience. Open Forum Infect Dis. 2023;10(1):ofac631. doi:10.1093/ofid/ofac631. PMID: 36632420. https://pubmed.ncbi.nlm.nih.gov/36632420/
    

23. Li J, Zhang W, Mei S, et al. Prevention and treatment of hardware-related infections in deep brain stimulation surgeries: a retrospective and historical controlled study. Front Hum Neurosci. 2021;15:707816. doi:10.3389/fnhum.2021.707816. PMID: 34512294. PMCID: PMC8427065. https://pmc.ncbi.nlm.nih.gov/articles/PMC8427065/
    

24. UC Davis Health. Deep Brain Stimulation Medical Safety Issues (patient safety PDF). https://health.ucdavis.edu/media-resources/neurology/documents/pdfs/pd-dbs/dbs-medical-safety-issues.pdf
    

25. Elliott MK, Momin A, Linton NWF, et al. Pacemaker and defibrillator implantation and programming in patients with deep brain stimulation. Arrhythm Electrophysiol Rev. 2019;8(2):119-124. PMCID: PMC6528032. https://pmc.ncbi.nlm.nih.gov/articles/PMC6528032/
    

26. Abbott Medical. Infinity DBS System summary of safety and effectiveness data (SSED), includes contraindications such as diathermy and other safety information. https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140009S039B.pdf
    

27. Lumsden DE, Selway R, Lin JP. A case of deep brain stimulation complicated by compulsive generator manipulation (Twiddler-like complication). Case report. PMCID: PMC6353532. https://pmc.ncbi.nlm.nih.gov/articles/PMC6353532/